Physician profile
Edward A White
NPI 1124175922
$8,880.61
in general payments reported to CMS, 2019-2025
27 companies · $2,566 in 2025
The $2,566 reported for 2025 was more than what 84% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.32 · 2021: $764 · 2022: $1,654 · 2023: $1,494 · 2024: $2,384 · 2025: $2,566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,443.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,443.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,950.72 | 2021-2025 | Rinvoq, Skyrizi, Mavyret |
| Takeda Pharmaceuticals U.S.A., INC. | $2,024.82 | 2021-2025 | Entyvio |
| Janssen Biotech, INC. | $741.50 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $723.83 | 2021-2025 | Xifaxan, Trulance |
| Genzyme Corporation | $373.74 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $327.85 | 2021-2024 | Dificid |
| Pfizer INC. | $252.14 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $221.83 | 2023-2025 | Dupixent |
| Gilead Sciences, INC. | $162.16 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $138.02 | 2024-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $137.57 | 2025 | Iqirvo |
| Daiichi Sankyo INC. | $129.24 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $127.60 | 2024-2025 | Zenpep |
| Qol Medical, LLC | $125.64 | 2021-2024 | Sucraid |
| Ardelyx, INC. | $94.37 | 2024-2025 | Ibsrela |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $70.20 | 2021-2023 | |
| Lilly USA, LLC | $43.15 | 2025 | Omvoh |
| Evoke Pharma, INC. | $38.86 | 2021-2024 | |
| Ironwood Pharmaceuticals, INC | $37.37 | 2022 | |
| Amgen INC. | $37.16 | 2023 | Avsola, Amjevita |
| Redhill Biopharma INC. | $23.50 | 2022 | |
| Biocompatibles, INC. | $19.32 | 2019 | |
| Intercept Pharmaceuticals, INC. | $19.14 | 2021 | |
| Stryker Corporation | $17.51 | 2025 | Surgicount |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.03 | 2023 | Cyltezo |
| Edwards Lifesciences Corporation | $15.11 | 2023 | |
| Micro-Tech Endoscopy USA, INC. | $11.23 | 2024 | Cold Snares |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.